Rising Global Burden of Drug-Resistant Neurological Disorders
The vagus nerve stimulation (VNS) device market in the BRICS countries is significantly shaped by the increasing number of drug-resistant neurological diseases, especially those involving epilepsy and neuropsychiatric problems in Brazil, Russia, India, China and South Africa. In particular, owing to factors such as high population levels, poor rural health care provision and delayed neurological detection, a high percentage of individuals develop refractory stages of epilepsy, especially in the urban-based tertiary hospitals.
In Brazil and South Africa, disparities between public and private healthcare systems play a significant role in the management of chronic neurological diseases. Public hospitals often face constraints in long-term access to newer-generation anti-epileptic drugs, leading to higher rates of uncontrolled seizure disorders. In Russia, a growing burden of post-stroke neurological complications among aging populations is contributing to increased cases of secondary epilepsy and treatment-resistant neurological dysfunction, reinforcing the clinical need for alternative therapeutic modalities.
Across BRICS nations, traumatic brain injuries from road traffic accidents and occupational hazards also contribute significantly to long-term neurological complications. In China and India in particular, high incidence of head trauma cases results in a growing population of patients with chronic seizure disorders that are difficult to manage pharmacologically. This evolving neurological burden is gradually increasing clinical awareness of VNS as a supportive intervention in specialized neurology and neurosurgery centers.
Expanding Portfolio of Therapeutic Indications
In the BRICS region, vagus nerve stimulation is expanding beyond epilepsy management into a broader range of neurological, psychiatric, and systemic applications. In China and India, growing clinical interest in treatment-resistant depression is driving exploratory use of VNS in psychiatric care settings, particularly in urban mental health institutes where conventional antidepressant therapies show limited efficacy in severe cases.
As for stroke recovery experiments involving VNS technology, this field has recently appeared both in Brazil and in South Africa, where neurologists and rehabilitation specialists are experimenting with neuroplasticity and motor function restoration with the help of vagus nerve stimulation after stroke. As far as Russia goes, there has been quite a lot of academic activity in neuromodulatory rehabilitation in recent years.
Also, pain syndromes and migraines have emerged as some of the main therapeutic focal points for treatment in BRICS nations in metropolitan regions such as São Paulo, Moscow, Shanghai, and Mumbai. Due to rising cases of stress-induced disorders and urban life diseases, doctors are increasingly turning to neuromodulation therapy rather than the use of drugs. With time, there is an expectation that the use of VNS will expand even further into the realms of psychiatry and neurology.
